ALK announced that authorities in France have issued a marketing authorisation for ALK's new house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet), ACARIZAX®. ACARIZAX® received regulatory approval in 11 European countries last year and is indicated for both allergic rhinitis and allergic asthma in adult patients not well controlled by symptom-relieving medications. ACARIZAX® was recently launched in Germany and Denmark.

Moreover, the recent, temporary suspension of production by ALK's main competitor has led to a shortage of supply for many doctors and allergy immunotherapy patients, especially in France. As the suspension continues and more allergy sufferers need to renew their prescriptions, the number of affected patients is expected to increase.